Journal of the American College of Cardiology · 2024 · 55 citations · 24 references
One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA<sub>2</sub>DS<sub>2</sub>-VASc score >4 and a stroke/SE risk of 2.2% per year. For these patients, the benefits of treatment with apixaban in preventing stroke/SE are greater than the risks. The opposite is true for patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score <4. A substantial intermediate group (CHA<sub>2</sub>DS<sub>2</sub>-VASc =4) exists in which patient preferences will inform treatment decisions. (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; NCT01938248).
24
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.8K citations · Full text
Gregory Y.H. Lip, Robby Nieuwlaat, Ron Pisters et al. · CHEST Journal · 2009 · 6.6K citations · Full text
Thrombosis, Venous Thrombosis, Cardiovascular Epidemiology +14
Subclinical Atrial Fibrillation and the Risk of Stroke
Jeff S. Healey, Stuart J. Connolly, Michael R. Gold et al. · New England Journal of Medicine · 2012 · 2K citations · Full text